Clinique Geoffroy Saint Hilaire, Groupe Ramsay Générale de Santé, Vascular Surgery Unit, Paris, France; CETI, Paris, France.
CETI, Paris, France.
Eur J Vasc Endovasc Surg. 2021 Mar;61(3):510-517. doi: 10.1016/j.ejvs.2020.08.048. Epub 2020 Oct 13.
Thirty per cent of cases of erectile dysfunction (ED)/male impotence are resistant to oral treatment. Half of these cases are due to blood drainage from the corpora cavernosa occurring too soon, due to cavernovenous leakage (CVL). The aim of this study was to report on an innovative treatment scheme combining pre- and post-operative haemodynamic assessment, venous embolisation, and open surgery for drug resistant ED caused by CVL.
An analysis of prospectively collected data, with clinical and haemodynamic pre- and post-operative assessment, was carried out. Forty-five consecutive patients operated on for drug resistant ED caused by CVL were evaluated pre-operatively and three months post-operatively by pharmacologically challenged penile duplex sonography (PC-PDS), pharmacologically challenged Erection Hardness Score (PC-EHS), and pharmacologically challenged computed caverno tomography (PC-CCT). Follow up consisted of patient interview, PC-PDS, PC-EHS and if needed PC-CCT.
Mean patient age was 43.9 ± 12.0 years (range 20-67). Forty-nine per cent of patients had primary ED. Patients with diabetes, a smoking habit, hypercholesterolaemia, and hypertension were 18%, 11%, 9%, and 4%, respectively. Three months post-operatively, PC-EHS increased from 2.0 ± 0.7 to 3.1 ± 0.74 (p < .001), with an EHS of 3 being the threshold allowing for penetration. Deep dorsal vein velocity, a haemodynamic marker of CVL, decreased from 14.2 ± 13.0 to 0.9 ± 3.5 cm/s (p < .001). After a 14.0 ± 10.7 month follow up, the primary success rate (clinical EHS ≥ 3, possible sexual intercourse with penetration, no vascular re-operation, no penile prosthesis implant) was 73.3%. Four patients (9%) underwent successful re-operation for persistent ED and CVL. Accordingly, compared with a possible penetration rate of 8.9% before surgery, 37 patients (secondary success rate: 82.2%) were able to achieve sexual intercourse with penetration. Type of ED (primary vs. secondary) and diabetes had no influence on the results. Thirty-two per cent of patients with secondary success achieved penetration with no medication.
After a 14 month follow up, pre-operative work up, embolisation, and open surgery during the same procedure allowed patients with ED resistant to oral medical to achieve intercourse with penetration.
30%的勃起功能障碍(ED)/男性勃起功能障碍病例对口服治疗有抗药性。其中一半的病例是由于海绵体静脉漏(CVL)导致血液从海绵体过早排出。本研究的目的是报告一种结合术前和术后血流动力学评估、静脉栓塞和开放手术治疗 CVL 引起的药物抵抗性 ED 的创新治疗方案。
对前瞻性收集的数据进行分析,进行临床和血流动力学术前和术后评估。对 45 例因 CVL 引起的药物抵抗性 ED 患者进行手术治疗,分别在术前和术后 3 个月通过药物刺激阴茎双功能超声(PC-PDS)、药物刺激勃起硬度评分(PC-EHS)和药物刺激计算机阴茎 CT(PC-CCT)进行评估。随访包括患者访谈、PC-PDS、PC-EHS 和如果需要 PC-CCT。
患者平均年龄为 43.9±12.0 岁(范围 20-67 岁)。49%的患者为原发性 ED。患有糖尿病、吸烟、高胆固醇血症和高血压的患者分别占 18%、11%、9%和 4%。术后 3 个月,PC-EHS 从 2.0±0.7 增加到 3.1±0.74(p<0.001),EHS 为 3 是允许穿透的阈值。深背静脉速度,CVL 的血流动力学标志物,从 14.2±13.0 减少到 0.9±3.5cm/s(p<0.001)。随访 14.0±10.7 个月后,原发性成功率(临床 EHS≥3,可能有性交,无血管再手术,无阴茎假体植入)为 73.3%。4 名患者(9%)因持续 ED 和 CVL 行成功再手术。因此,与术前可能穿透率 8.9%相比,37 名患者(次要成功率:82.2%)能够进行有穿透性的性交。ED 的类型(原发性与继发性)和糖尿病对结果没有影响。32%的继发性成功患者无需药物即可实现穿透。
在 14 个月的随访后,术前检查、栓塞和开放手术在同一程序中允许对口服药物有抗药性的 ED 患者进行有穿透性的性交。